Dr John Logue, Consultant Clinical Oncologist
Dr John Logue
Consultant Clinical Oncologist
Dr John Logue MB MRCP FRCR
Consultant Clinical Oncologist
Dr John Logue
Consultant Clinical Oncologist MB MRCP FRCR
Dr Logue is a Consultant Clinical Oncologist
Areas of expertise
- Prostate cancer
- Urological oncology
- Brachytherapy
- Image guided radiotherapy (IGRT)
- Intensity modulated radiotherapy (IMRT)
About Dr John Logue
GMC number: 2554879
Year qualified: 1981
Place of primary qualification: University of Glasgow
Dr Logue is an experienced oncologist with a specialised interest in uro-oncology. He has been instrumental in the continued introduction and advancement of radiation therapy techniques, including brachytherapy, IMRT, and image-guided radiotherapy at the Christie Hospital.
Dr Logue currently serves as the Director of Clinical Oncology at the Christie Hospital. His areas of expertise include urological oncology and technological advances in radiation therapy. He has a particular focus on brachytherapy, a procedure that involves placing radioactive material inside the body to treat cancer.
Since his appointment in 2010, Dr Logue has been dedicated to improving patient outcomes through innovative treatment methods and cutting-edge technology. His role involves not only treating patients but also guiding the hospital in delivering the best possible care and operating safely and efficiently.
In addition to his clinical responsibilities, Dr Logue is actively involved in research and development within his field. His interests lie in exploring new techniques and technologies to enhance the effectiveness of radiation therapy for urological cancers.
Dr Logue's commitment to excellence in oncology ensures that patients at the Christie Hospital receive the highest standard of care. His expertise in urological oncology and advanced radiation therapy techniques makes him a leading figure in his field.
Areas of expertise
- Clinical oncology
- Urological oncology
Professional memberships
Articles by Dr John Logue
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 chhip trial
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial
Updated analysis of the phase iii, double- blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (crpc) patients with bone metastases (alsympca)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial
Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy
Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity
Pd-0178: parameterised rectal dose and associations with latetoxicity in high-dose-rate prostate brachytherapy
Ep-1223: endorectal balloons in prostate cancer radiotherapy: effects on seminal vesicle positioning
Alpha emitter radium-223 and survival in metastatic prostate cancer
